Conditions that activate abnormal AR trans-activation through AR mutations [4,5], amplification of AR [6], or androgen-independent signaling pathways [7,8] can lead to or be a result of the development of prostatic diseases or androgen refractory PCa. This evidence concerns the gene AR and posterior cortical atrophy.